Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Suzhou Weast Biotechnology Co. Ltd. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution of this matter involves 1 distinct examiner, pointing to a very focused interaction with the USPTO. This singular focus suggests that the company's current patenting efforts are concentrated on a specific technological advancement or a single application.
The company's active prosecution is limited to 1 distinct art unit, which centralizes the technical scrutiny of its claims. SARA ELIZABETH BELL is the busiest examiner for the company, currently overseeing 1 pending office action. Since this examiner is the only one with an active case, the company's immediate progress in the patent office is entirely dependent on her individual review process.
With 1 pending office action and a single point of contact, the administrative complexity of the portfolio is minimal. However, the reliance on SARA ELIZABETH BELL for the only active matter means that her specific examination style will be the primary factor in the company's short-term success. The concentration in the Biotechnology & Pharmaceuticals sector allows for a dedicated response to the specific issues raised in the outstanding action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920139 | APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE | BELL, SARA ELIZABETH | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920139 | APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE | BELL, SARA ELIZABETH | 23d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17920139 | APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE | BELL, SARA ELIZABETH | 1625 | §103§112 | Non-Final OA | 23d | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Weast Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Bell has the most, with 1 of Suzhou Weast Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
